Ceva Animal Health (Ceva) – the #5th largest animal health global player, present in 110 countries, unveils its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia.
Ceva Phylaxia, with over a century of expertise has been at the forefront of combating major livestock diseases through innovative research and vaccine development.
This development will establish a 7,000 m2 plant in Monor, Hungary withthe most advanced technologies,whereCeva will produce fermentation-based multicomponent inactivated vaccines for animals.
For over 20 years, Ceva has been a strong advocate for prevention through vaccination, heavily investing in preventive medicine to significantly improve the health of husbandries but also to fight zoonotic and emerging diseases, contributing to prepare for future pandemics.
Today, 54% of Ceva’s R&D budget is dedicated to vaccine development and the company already provides more than 50 vaccines to fight 19 zoonotic diseases.
Ceva is the most innovative animal health company in vaccine technologies and one of the leading players on a global scale. Ceva is the first and only company to have developed a mRNA platform for animals in less than three years, the historical world leader in vector vaccines for poultry, and remains the world leader in broiler vaccination and #1 in hatchery vaccination. The company has also extensive global expertise in autogenous vaccines.
With this investment, it will further strengthen its position, producing more than 8 billion doses of vaccines in this new manufacturing plant annually, on top of other animal health products.
“Building a new facility is always a significant milestone in the life of a company. In Hungary, we already benefit from a strong historical expertise with our Ceva Phylaxia campus. With the addition of this new production unit in Monor, we aim to create new synergies to advance preventive medicine. This project reflects our commitment to supporting farmers worldwide by developing tailored solutions to tackle emerging diseases and new variants. It embodies our ambition to build a promising future for our company, employees, and partners, both in Hungary and internationally, while strengthening our research and development capabilities.” says Marc Prikazsky, Chairman and CEO of Ceva Animal Health.
The new plant is scheduled to start operations at the end of 2026.
